Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 43.12% is in line with its 5-year average of 43.09%, around the middle of its 5-year range (25.79%–53.56%).
0.90% above its 12-month average of 42.74%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 34.95%.
EBITDA MARGIN
43.12%
EBITDA MARGIN AVG TTM
42.74%
EBITDA MARGIN AVG 3Y
40.30%
EBITDA MARGIN AVG 5Y
43.09%
EBITDA MARGIN AVG 10Y
47.16%
EBITDA MARGIN AVG 15Y
45.17%
EBITDA MARGIN AVG 20Y
44.47%
CURRENT VS TTM AVG
+0.90%
CURRENT VS 3Y AVG
+7.01%
CURRENT VS 5Y AVG
+0.06%
CURRENT VS 10Y AVG
-8.57%
CURRENT VS 15Y AVG
-4.55%
CURRENT VS 20Y AVG
-3.04%
Market Cap
$191.81B
EBITDA Margin
48.42%
TTM Avg
49.59%
3Y Avg
48.46%
5Y Avg
47.82%
Market Cap
$187.34B
EBITDA Margin
49.12%
TTM Avg
32.26%
3Y Avg
34.27%
5Y Avg
33.90%
Market Cap
$176.83B
EBITDA Margin
24.35%
TTM Avg
24.15%
3Y Avg
24.77%
5Y Avg
25.59%
Market Cap
$244.65B
EBITDA Margin
24.44%
TTM Avg
24.78%
3Y Avg
25.35%
5Y Avg
27.67%
Market Cap
$149.35B
EBITDA Margin
30.87%
TTM Avg
31.21%
3Y Avg
32.47%
5Y Avg
31.98%
Market Cap
$135.50B
EBITDA Margin
35.99%
TTM Avg
34.83%
3Y Avg
32.83%
5Y Avg
33.22%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Amgen Inc. (AMGN) | $204.97B | 43.12% | 42.74% | 40.30% | 43.09% |
| Novo Nordisk A/S (NVO)vs › | $191.81B | 48.42% | 49.59% | 48.46% | 47.82% |
| Gilead Sciences, Inc. (GILD)vs › | $187.34B | 49.12% | 32.26% | 34.27% | 33.90% |
| Abbott Laboratories (ABT)vs › | $176.83B | 24.35% | 24.15% | 24.77% | 25.59% |
| Thermo Fisher Scientific Inc. (TMO)vs › | $244.65B | 24.44% | 24.78% | 25.35% | 27.67% |
| Pfizer Inc. (PFE)vs › | $157.50B | 32.51% | 34.72% | 32.84% | 32.73% |
| AstraZeneca PLC (AZN)vs › | $257.66B | 33.16% | 30.52% | 27.50% | 25.68% |
| Danaher Corporation (DHR)vs › | $149.35B | 30.87% | 31.21% | 32.47% | 31.98% |
| Intuitive Surgical, Inc. (ISRG)vs › | $135.50B | 35.99% | 34.83% | 32.83% | 33.22% |
| Vertex Pharmaceuticals Incorporated (VRTX)vs › | $131.05B | 41.14% | 20.45% | 32.86% | 36.27% |
Gross Margin
72.7%
EBITDA Margin
43.1%
Operating Margin
33.2%
Net Margin
22.9%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 34.95% |
| 2026-03-31 | 43.88% |
| 2025-12-31 | 51.27% |
| 2025-09-30 | 40.11% |
| 2025-06-30 | 43.47% |
| 2025-03-31 | 31.48% |
| 2024-12-31 | 40.81% |
| 2024-09-30 | 40.49% |
| 2024-06-30 | 39.45% |
| 2024-03-31 | 32.09% |
| 2023-12-31 | 32.35% |
| 2023-09-30 | 42.24% |
| 2023-06-30 | 51.25% |
| 2023-03-31 | 46.21% |
| 2022-12-31 | 45.93% |
| 2022-09-30 | 52.57% |
| 2022-06-30 | 45.56% |
| 2022-03-31 | 53.56% |
| 2021-12-31 | 46.10% |
| 2021-09-30 | 48.14% |
| 2021-06-30 | 25.79% |
| 2021-03-31 | 50.33% |
| 2020-12-31 | 43.43% |
| 2020-09-30 | 52.22% |
| 2020-06-30 | 52.42% |
| 2020-03-31 | 52.78% |
| 2019-12-31 | 44.38% |
| 2019-09-30 | 52.01% |
| 2019-06-30 | 54.15% |
| 2019-03-31 | 53.39% |
| 2018-12-31 | 46.10% |
| 2018-09-30 | 47.83% |
| 2018-06-30 | 54.73% |
| 2018-03-31 | 57.56% |
| 2017-12-31 | 46.43% |
| 2017-09-30 | 50.29% |
| 2017-06-30 | 55.35% |
| 2017-03-31 | 57.01% |
| 2016-12-31 | 51.03% |
| 2016-09-30 | 52.14% |
| 2016-06-30 | 51.02% |
| 2016-03-31 | 52.89% |
| 2015-12-31 | 46.51% |
| 2015-09-30 | 50.01% |
| 2015-06-30 | 48.32% |
| 2015-03-31 | 50.59% |
| 2014-12-31 | 37.22% |
| 2014-09-30 | 39.93% |
| 2014-06-30 | 46.49% |
| 2014-03-31 | 41.63% |
| 2013-12-31 | 32.55% |
| 2013-09-30 | 41.62% |
| 2013-06-30 | 39.05% |
| 2013-03-31 | 40.56% |
| 2012-12-31 | 30.78% |
| 2012-09-30 | 39.59% |
| 2012-06-30 | 41.50% |
| 2012-03-31 | 42.89% |
| 2011-12-31 | 35.82% |
| 2011-09-30 | 20.03% |
| 2011-06-30 | 40.24% |
| 2011-03-31 | 42.26% |
| 2010-12-31 | 34.60% |
| 2010-09-30 | 45.39% |
| 2010-06-30 | 46.48% |
| 2010-03-31 | 48.25% |
| 2009-12-31 | 36.23% |
| 2009-09-30 | 49.24% |
| 2009-06-30 | 46.05% |
| 2009-03-31 | 48.00% |
| 2008-12-31 | 37.62% |
| 2008-09-30 | 45.19% |
| 2008-06-30 | 38.36% |
| 2008-03-31 | 46.53% |
| 2007-12-31 | 36.29% |
| 2007-09-30 | 21.24% |
| 2007-06-30 | 37.88% |
| 2007-03-31 | 44.59% |
| 2006-12-31 | 31.00% |
| 2006-09-30 | 44.55% |
| 2006-06-30 | 15.32% |
| 2006-03-31 | 45.17% |
| 2005-12-31 | 40.32% |
| 2005-09-30 | 47.62% |
| 2005-06-30 | 47.60% |
| 2005-03-31 | 47.94% |
| 2004-12-31 | 38.23% |
| 2004-09-30 | 25.06% |
| 2004-06-30 | 45.88% |
| 2004-03-31 | 47.12% |
| 2003-12-31 | 39.72% |
| 2003-09-30 | 46.47% |
| 2003-06-30 | 48.43% |
| 2003-03-31 | 47.24% |
| 2002-12-31 | 447.74% |
| 2002-09-30 | -153.56% |
